PM360’s December Innovations Issue Open For Submissions
New York, NY (PRWEB) September 12, 2016 -- PM360’s annual Innovations Issue, published in December, has become the industry’s must-read guide to the latest innovations happening across the industry. Now in its fifth year, the issue covers the most innovative companies, startups, divisions, products, services, and strategies from the past year.
“As the industry continues to face new challenges, companies continue to work on solutions for how to overcome them. But at the rapid pace that these new solutions and startup companies emerge, it can be difficult for those in the industry to keep up,” says Anna Stashower, CEO and Publisher of PM360. “We were the first in the industry to establish an annual guide that details the most recent and relevant innovations that pharma marketers need to know about.”
All submissions are free, and there is no limit to how many submissions one company can make. Submissions must fit into one of 6 categories:
- Companies (any company is eligible to enter, but they must detail what they have done over the past year that makes them truly innovative)
- Startups (a startup is defined by a new company formed within the last 5 years, but they will be evaluated on their most recent work)
- Divisions (any offshoot or part of a company that was developed within the last 16 months to solve a particular problem or challenge the industry is facing)
- Products (new software, apps, drug delivery devices, or anything else designed within the last year to help pharma to be more successful)
- Services (new offerings from companies within the last year that makes the jobs of those in the life sciences easier)
- Strategies (never before tried approaches that are changing how the industry operates)
Submissions will be evaluated by PM360’s editors. Each submission statement must be at minimum 300 words. The submission statement should answer the following questions:
- What makes your company, division, product, service or strategy innovative?
- How recent is your innovation? (i.e., What did your company do this year? When was your startup founded? How long has your product or service been on the market?)
- How is your innovation improving or how will it improve the healthcare or life sciences industries?
- What challenges did you face in creating something innovative and how did you overcome them?
- Do you have any stats that demonstrate how effective your innovation has been to this point?
Along with the written submission statement, entrants can also send any photos, graphics, charts or other images that can further illustrate the innovation and how it works. Images should be sent as a JPEG, TIFF, or PDF and be approximately 4x5-inches and 300 dpi.
All submissions must be sent to editorial(at)pm360online(dot)com by October 21.
For more information, contact Andrew Matthius, Senior Editor, PM360, at 646-300-8113 or andrew(dot)matthius(at)pm360online(dot)com.
About PM360
PM360 is the premier, must-read magazine for marketing decision makers in the pharmaceutical, biotech, and medical device industries. Published monthly, PM360 is the only journal that focuses on delivering the full spectrum of practical information necessary for product managers and pharmaceutical marketing professionals to succeed in the complex and highly regulated healthcare environment.
The journal’s targeted and insightful editorial focuses on issues that directly impact critical decision making, including: Planning and implementation of cutting edge strategies, trends, the latest technological advances, branding/marketing, advertising/promotion, patient/professional education, sales, market research, PR, and leadership. Additionally, the “360” in the title signifies the span of this critical, how-to info with personal and career insights for an enjoyable and thought-provoking read.
By providing the full circle of enriching content, PM360 is truly an indispensable tool for busy and productive marketing professionals to stay at the top of their game.
Jeremi Gill, Makovsky, +1 212-508-9617, [email protected]
Share this article